InvestSMART

Island Pharmaceuticals Limited (ASX: ILA) - Announcements

- Current share price for ILA : $0.375

ASX company news and announcements for Island Pharmaceuticals Limited (ILA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Island Pharmaceuticals Limited (ILA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Island Pharmaceuticals Limited (ILA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Island Pharmaceuticals Limited (ILA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$111 Investor presentation 5 Feb 2026 9:57AM $0.420 $0.375 fallen by 10.71%
$111 Proposed issue of securities - ILA 4 Feb 2026 9:34AM $0.390 $0.375 fallen by 3.85%
$111 $9m placement to advance US biodefence opportunity 4 Feb 2026 9:34AM $0.390 $0.375 fallen by 3.85%
$111 FDA confirms Galidesivir approval pathway 4 Feb 2026 9:29AM $0.390 $0.375 fallen by 3.85%
$111 Trading Halt 2 Feb 2026 8:43AM $0.390 $0.375 fallen by 3.85%
$111 Investor Presentation 27 Jan 2026 8:33AM $0.430 $0.375 fallen by 12.79%
$111 Quarterly Appendix 4C and Activities Report 27 Jan 2026 8:32AM $0.430 $0.375 fallen by 12.79%
$111 US Patent Granted for Galidesivir in filoviridae viruses 7 Jan 2026 9:44AM $0.410 $0.375 fallen by 8.54%
$111 Notification regarding unquoted securities - ILA 6 Jan 2026 9:40AM $0.440 $0.375 fallen by 14.77%
$111 Ongoing engagement with the US FDA 5 Jan 2026 8:41AM $0.435 $0.375 fallen by 13.79%
$111 Agreement with Texas Biomed for Galidesivir Program 17 Dec 2025 8:36AM $0.465 $0.375 fallen by 19.35%
$111 Change in substantial holding 9 Dec 2025 12:14PM $0.475 $0.375 fallen by 21.05%
$111 Change in substantial holding 9 Dec 2025 12:12PM $0.475 $0.375 fallen by 21.05%
$111 Change in substantial holding 9 Dec 2025 12:08PM $0.470 $0.375 fallen by 20.21%
$111 Island expands Galidesivir IP with US Patent Grant 5 Dec 2025 9:52AM $0.545 $0.375 fallen by 31.19%
$111 Additional FDA Submission completed for Galidesivir 4 Dec 2025 8:27AM $0.510 $0.375 fallen by 26.47%
$111 Change of Director's Interest Notice - CN & JC 3 Dec 2025 5:06PM $0.510 $0.375 fallen by 26.47%
$111 Options exercised raises $1million 3 Dec 2025 8:37AM $0.545 $0.375 fallen by 31.19%
$111 Cleansing Notice 3 Dec 2025 8:32AM $0.545 $0.375 fallen by 31.19%
$111 Application for quotation of securities - ILA 3 Dec 2025 8:30AM $0.545 $0.375 fallen by 31.19%
$111 Coalition acceptance to advance US procurement & stockpiling 24 Nov 2025 8:43AM $0.520 $0.375 fallen by 27.88%
$111 Island engages advisers to advance biodefence strategy 20 Nov 2025 9:34AM $0.490 $0.375 fallen by 23.47%
$111 FDA agrees Animal Rule pathway and PRV eligibility 17 Nov 2025 9:27AM $0.425 $0.375 fallen by 11.76%
$111 Change of registered address 14 Nov 2025 8:53AM $0.425 $0.375 fallen by 11.76%
$111 Webinar - FDA response to Galidesivir program 13 Nov 2025 2:34PM $0.425 $0.375 fallen by 11.76%

26 - 50 of 433 results

Page 2 of 18

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.